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Abstract
Background: Similar to many developed countries, vaccination against human papillomavirus (HPV) is provided
only to girls in New Zealand and coverage is relatively low (47% in school-aged girls for dose 3). Some jurisdictions
have already extended HPV vaccination to school-aged boys. Thus, exploration of the cost-utility of adding boys’
vaccination is relevant. We modeled the incremental health gain and costs for extending the current girls-only
program to boys, intensifying the current girls-only program to achieve 73% coverage, and extension of the
intensive program to boys.
Methods: A Markov macro-simulation model, which accounted for herd immunity, was developed for an annual
cohort of 12-year-olds in 2011 and included the future health states of: cervical cancer, pre-cancer (CIN I to III),
genital warts, and three other HPV-related cancers. In each state, health sector costs, including additional health
costs from extra life, and quality-adjusted life-years (QALYs) were accumulated. The model included New Zealand
data on cancer incidence and survival, and other cause mortality (all by sex, age, ethnicity and deprivation).
Results: At an assumed local willingness-to-pay threshold of US$29,600, vaccination of 12-year-old boys to achieve
the current coverage for girls would not be cost-effective, at US$61,400/QALY gained (95% UI $29,700 to $112,000;
OECD purchasing power parities) compared to the current girls-only program, with an assumed vaccine cost of US
$59 (NZ$113). This was dominated though by the intensified girls-only program; US$17,400/QALY gained (95% UI:
dominant to $46,100). Adding boys to this intensified program was also not cost-effective; US$128,000/QALY
gained, 95% UI: $61,900 to $247,000).
Vaccination of boys was not found to be cost-effective, even for additional scenarios with very low vaccine or
program administration costs – only when combined vaccine and administration costs were NZ$125 or lower per
dose was vaccination of boys cost-effective.
Conclusions: These results suggest that adding boys to the girls-only HPV vaccination program in New Zealand is
highly unlikely to be cost-effective. In order for vaccination of males to become cost-effective in New Zealand,
vaccine would need to be supplied at very low prices and administration costs would need to be minimised.
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Background
Most developed countries have now implemented vaccin-
ation against human papillomavirus (HPV) infection of
pre-adolescent girls. This development has been supported
by cost-effectiveness analyses in over 40 countries that have
almost universally concluded that vaccination of girls is
cost-effective [1]. In low resource settings, the GAVI alli-
ance has announced that it will co-finance the HPV vaccine
in the poorest countries, with supplier-agreed vaccine
prices of about US$5 per dose. In addition to the benefits
to women of reduced cervical intra-epithelial neoplasia
(CIN) and cervical cancer, HPV vaccination can reduce
other cancers and diseases which impact both sexes, includ-
ing anal and oropharyngeal cancers and genital warts. As
such, some public health professionals and researchers pro-
file the ethical debate of the exclusion of boys in a vaccin-
ation program from which they could reap additional
health benefits. In recent decades, data suggest that inci-
dence rates for HPV-related anal and oropharynx cancer,
affecting both sexes, have been increasing in many coun-
tries, including the US [2], and Australia [3,4] and markedly
in 50–69 year-old males in New Zealand [5]. Vaccinating
males as well as females will confer more benefit than vac-
cinating females only, but the extent of the incremental
benefit will critically depend on coverage in females. Vac-
cination also substantially decreases disease burden related
to genital warts, as reported in Australia [6], Sweden [7],
and New Zealand [8,9].
Health authorities, including the Advisory Committee for
Immunization Practices for the US Centers for Disease
Control and Prevention, have recommended the vaccin-
ation of boys [10]. While vaccination of boys has been
available through private health services in the US,
Australia became the first country to offer publicly-funded
HPV boys vaccination (quadrivalent vaccine Gardasil®) in
2013 [11], although the cost-effectiveness and equity benefit
of this program has been criticized [12]. To date, cost-
effectiveness analyses of the inclusion of boys into existing
girls’ programs have had varying results. HPV-related dis-
ease may be reduced in males either through direct benefits
to vaccinated males or herd immunity effects to unvaccin-
ated males due to sexual contact with vaccinated females or
males. The cost-effectiveness of adding boys to existing vac-
cination programs depends on a number of model parame-
ters and assumptions, including: the coverage achieved in
females, since this will determine the predicted herd im-
munity (e.g., in dynamic models) for heterosexual males de-
rived from vaccinating girls [13]; the HPV-related burden
of disease in males (which is lower than in females [1]); the
proportion of HPV-related disease in men-who-have-sex-
with-men (MSM; difficult to model for young cohorts and
rarely explicitly included in population models) [1]; the cost
of the vaccine and administration; the vaccine efficacy and
duration of protection; the number of diseases included in
analyses, and the associated burden of those diseases in the
setting of interest.
When vaccine coverage is high (e.g., over 70%) in fe-
males, modeling indicates that non-vaccinated hetero-
sexual males would receive high levels of health benefits
via herd immunity [13-15]. For example, in a dynamic
Canadian heterosexual population model with a vaccin-
ation coverage of 70% for 12-year-old girls and 0% of
boys, HPV-16/18 overall population prevalence was re-
duced by 64% [13]. Adding 70% coverage for boys to this
program only decreased this HPV-16/18 prevalence by
another 24%. Therefore additionally vaccinating boys, at
higher coverage rates, was less cost-effective than in-
creasing coverage for girls [13].
For lower vaccination coverage levels (e.g., <50%) one
study found that increased coverage for females was more
cost-effective than adding boys to a girls-only vaccination
program, even if the intensified girls program incurred high
costs of US$350 per additional girl vaccinated [16]. A re-
cent review of HPV vaccination cost-effectiveness modeling
concluded that increasing female coverage appears to be a
better investment, but that vaccination of boys may be
cost-effective when female coverage is less than 50% and it
costs about US$400-500 per vaccinated girl/boy [1].
Among MSM, herd immunity benefits are obviously
lower for girls-only vaccination and depend in part on
behavior patterns for non-exclusive MSM in the popula-
tion. Targeted vaccination of MSM may be cost-effective
in some settings (e.g., those with high HIV rates), par-
ticularly at younger ages [17]. However, targeted HPV
vaccination of a young cohort prior to HPV exposure of
MSM is a considerable challenge for vaccination pro-
grams to achieve (and we know of no settings where it
has been effectively operationalized).
Another important determinant of the cost-effectiveness
is vaccine and associated administration costs. Many gov-
ernments have negotiated vaccine prices with suppliers for
large-scale public programs and these costs are often not
readily available to the public (although vaccine prices per
dose of about US$100 have been used in past studies [1]).
Importantly, costs may continue to drop in developed
countries and two-dose vaccination (which appear to be
nearly as effective as three-dose regimens) may be increas-
ingly introduced [18].
The goal of this research was to examine the cost-
effectiveness of adding boys to a girls-only program in New
Zealand. This study makes use of national, high-quality
health and costing data and includes a number of health
outcomes which affect both males and females. We mod-
eled cost-effectiveness for two different coverage rates and
also modeled a suite of scenarios for changes in vaccine
and administration costs. Such scenarios may facilitate
forward-thinking by policy-makers as vaccine prices con-
tinue to decline.




The study methods followed the Burden of Disease
Epidemiology, Equity and Cost-Effectiveness Programme
(BODE3) Protocol [19]. We adapted a previous Markov
model on the cost-utility of girls-only HPV vaccination
[20], to estimate quality-adjusted life years (QALYs) gained
and net health system costs, for girls-only and girls and
boys vaccination. The QALY metric captures both years of
life lost from premature death, and loss of quality of life
through morbidity. To value this health loss, we used dis-
ability weights (DWs), as outlined below. We formally use
the term QALYDW in this paper’s Methods and Results,
but shorten it to QALY in other sections.
The two main adaptations were adding vaccine and
administrative costs per vaccinated boy, and additional
reductions in HPV infection due to additionally vaccin-
ating boys.
Health system costs included both direct intervention
costs and downstream health system costs incurred/
averted. A 3% discount rate applied to costs and quality-
adjusted life years (QALYsDW) gained. Currency conver-
sions were conducted using the OECD purchasing
power parity (PPP) estimates, to eliminate the differ-
ences in price levels between countries [21]. In 2011, the
PPP values were US$1 = NZ$1.48.
HPV vaccination was modeled as preventing CIN I-III,
cervical, anal, oropharyngeal and vulval cancers and
anogenital warts (Figure 1) using rates of all-cause mor-
tality, excess mortality rates from cancer [22], and inci-
dence rates for cancer [23] and morbidity states [24].
Vaginal and penile cancers were excluded due to their
small contribution to the HPV16/18-related cancer bur-
den (<3%). Recurrent respiratory papillomatosis (RRP)
was excluded due to sparse data. Cervical cancer screen-
ing programs were assumed to continue in New Zealand,
but these costs were excluded from our analyses.
Model input parameters
Input parameters are shown in Table 1 (HPV prevalence
reduction and vaccination costs) and Additional file 1:
Tables S1 and S2, and briefly described below.
Morbidity
Disability weights (DWs) for each disease state were
used, with uncertainty, on a scale from 0 (full health) to
1.0 (death) (Additional file 1: Table S1). Expected popu-
lation morbidity (i.e., due to disease other than HPV-
related disease) was allowed for by using the average
ethnic and age-specific prevalent years of life lived in
disability from the New Zealand Burden of Disease
Study [19], limiting the maximum QALYsDW gained with
increasing age. Consider a non-Māori male aged 50–54
with oropharyngeal cancer in the remission phase (ex-
pected DW= 0.248, although actually modeled with un-
certainty), with an expected background morbidity of
Figure 1 Stylized Markov model for HPV-related disease states. r1 = rates of all-cause mortality from population lifetables, by sex, age,
ethnicity (Māori, non-Māori) and area deprivation (approximate tertiles), and projected to future. Source: [22]. r2i = excess mortality rates of death
from cancer i, by sex, age, ethnicity and deprivation, and by time since diagnosis. Source: [23] r3i = incidence rates for cancer i, by sex, age,
ethnicity and deprivation. Source: [24] r4j = incidence rates for morbidity states j, by sex and age (and ethnicity for CIN I, CIN II/III and anogenital
warts). Source: [20].
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Table 1 Intervention parameters: vaccination coverage of 12-year olds, reduction in future HPV and intervention costs
Intervention Vaccination coverage Beta distribution for
vaccination coverage
Reduction in HPV infection for central estimate
of vaccination coverage only (95% uncertainty interval)
Vaccination costs
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0.112 [19]; his expected QALYsDW awarded in that year
would be (1–0.248) × (1–0.112) = 0.668.
Incidence and survival
Cancer incidence rates were those predicted for 2011
with trends projected into the future based on regres-
sions on New Zealand Cancer Registry data [25]. There-
fore, when the model was run without intervention
effects, the model produced the same disease data as the
input dataset. Incidence rates for other diseases and the
proportion of disease due to HPV 16/18 or 6/11 were
compiled from various sources, including national can-
cer registration data [24] and screening program infor-
mation [26]. Australian burden of disease models were
used to allocate durations for each cancer in diagnosis
and treatment, remission, pre-terminal and terminal
states, with attendant DWs sourced from the Global
Burden of Disease 2010 [27] with modification to the
New Zealand distribution of cancers [19]. Cancer survi-
vors were modeled in the cancer state for five cycles ac-
cumulating QALYs with morbidity adjustment via the
DWs, then returned to the healthy state.
Health system cost parameters
Just as QALYsDW were awarded to each individual as
they traveled through states, so were health system costs.
We used routine, linked administrative health data for
the entire New Zealand population with costs attached,
as described elsewhere [19]. We assigned health system
costs by sex and age to the healthy state (see Additional
file 1: Table S2). The added cost for cancer patients at
different stages of care (i.e., diagnosis, remission, ter-
minal) were estimated using gamma regression, as per
the previous research in the BODE3 Program for girls-
only vaccination [20]. The added cost for other disease
states (CIN I-III and warts) were simple averages. All
health system costs were measured in 2011 New Zealand
dollars.
Interventions
Effectiveness: vaccination coverage and future reduction in
HPV prevalence
The vaccination coverage levels were assumed to be the
same for both boys and girls for two interventions: (1G and
1G+ B) the current girls’ 3-dose coverage level in 12–13
year olds in New Zealand (45-56%) [28]; and (2G and 2G+
B) Australia’s coverage level of 12–13 year old girls (73%),
with no catch-up vaccination modeled. We suspect that
similar coverage is a reasonable assumption for school-
based vaccination programs, provided that sufficient infor-
mation is communicated to parents and providers about
the direct benefits to males of HPV vaccination. We note
that a recent review found a preference to vaccinate females
over males among both health care providers and parents
[29], which could lead to lower coverage for boys than girls.
However, the review authors noted that in many studies the
direct benefits to males were not communicated and the
main reason given for refusal was the lack of perceived dir-
ect benefit for males.
The reduction in HPV infections for varying programs
of girls-only and girls and boys vaccination was esti-
mated by meta-regressions on outputs from Brisson et
al’s (2011) dynamic Canadian model [13], which allowed
for changing likelihood of acquiring HPV over time and
herd immunity effects. This model used gender and
age-specific sexual behavior characteristics (e.g., partner
acquisition rates, mixing between age groups) as risk
factors for HPV infection. Thus, our Markov macro-
simulation models assumed similar sexual behaviors to
that in the Canadian model. We considered this gener-
ally reasonable on the basis of available comparable
data on age of sexual debut and the epidemiology of
genital warts. While data on adolescent sexual behavior
are sparse, age of sexual debut are similar between
Canada [30] and New Zealand [31]. Likewise, incidence
of genital warts peak in the same age groups (<25 years
old) in both countries [32,33].
Briefly, we fitted regression models to their output for
the median, 10th and 90th percentile reductions in HPV
prevalence with vaccine coverage as an independent
variable for two types of HPV (6/11 and 16/18) for girls-
only vaccination, doubled the uncertainty range on the
logistic scale to account for ‘structural’ uncertainty when
using the results in New Zealand, and then used these
median and widened uncertainty intervals to generate
Beta distribution parameters to sample in the model
(method details described in an Appendix to the parallel
study on girls-only vaccination [20]). For the marginal
impact of boys, we assumed a correlation of 0.5 between
the HPV prevalence impacts of girls-only vaccination
and the marginal impact of adding boys, and calibrated
Beta distributions to achieve the uncertainty reported in
[13] for the marginal impact of adding boys’ vaccination.
Examples of future long-term HPV reduction for speci-
fied vaccine coverage levels are shown in Table 1. We
assumed that the vaccine efficacy was 99% and had a
duration of 20 years, that the effect of HPV vaccination
was in a ‘steady state’ and that vaccine immunogenicity
was the same in both boys and girls.
Intervention costs
The vaccination costs were calculated per fully vaccinated
girl/boy, based on the annual vaccine cost paid by the Min-
istry of Health (in 2011), resulting in the vaccine cost per
dose of NZ$113 (Table 1). The delivery/administration
costs of three main interventions were NZ$141 or NZ$126
per dose depending on the method of delivery (i.e., in
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schools and primary care settings or in schools only). These
costing data were based on official Ministry of Health data
which include funding to cover program management
(a component which is often omitted from ‘administration
costs’ of other studies). The vaccination costs were multi-
plied by three doses, and then assigned for each fully vacci-
nated member of the cohort (allowing for vaccine
coverage); incomplete vaccine courses were not considered.
We used a discount rate of 3% and as for health system
costs, all intervention costs were measured in 2011 New
Zealand dollars.
In scenario analyses, we explored reductions in vaccine
cost-per-dose at several levels of reduction down to $1 and
lower administrative costs (NZ$19 per dose). We also con-
ducted a scenario analysis which removed the herd immun-
ity cancer reduction benefits for males in the girls-only
vaccination program (1G). We compared these results with
the benefits of adding boys to the vaccination program
(1G + B) and included MSM-attributable warts and can-
cers in the disease incidence data that populates the
model. We also performed a threshold analysis to estimate
the maximum cost per delivered vaccine dose (including
vaccine and administration costs) which would allow vac-
cination of boys in addition to girls to be cost-effective
compared to girls only vaccination.
Considering uncertainty and performing cost-
effectiveness analysis
Monte Carlo simulation was used, with 2,000 draws from
input parameter distributions. Incremental QALYsDW, costs
and incremental cost-effectiveness ratios (ICERs) were cal-
culated for each draw of Monte Carlo simulation. All mod-
eling and uncertainty analyses were undertaken in TreeAge
Pro 2012. ICERs were calculated for each intervention in-
cluding boys (1G + B and 2G+ B), compared to the equiva-
lent intervention for girls-only (1G and 2G) and compared
to no vaccination program. In line with contextualizing
ICER results with GDP per capita comparisons [34], we
made such comparisons for the New Zealand setting. Be-
cause there is no universally accepted threshold in New
Zealand for describing interventions as being “cost-effect-
ive” or not, we relied on the WHO definition and used a
nominal GDP per capita of NZ$45,000 in 2011 (US
$29,600) as being such a threshold. Using the GDP per
capita level is based on the WHO description of interven-
tions below this value as being ‘very cost-effective’ (for the
WPROA Region to which New Zealand belongs [34]).
Results
The modeling results indicated that the estimated inter-
vention costs rose with increasing coverage levels and
when adding boys to the girls-only programs (Table 2).
QALYsDW gained increased with higher coverage levels.
Adding boys to the 2011 girls-only program (assuming
the same level of coverage was obtained in boys) pro-
duced a similar number of QALYsDW gained (350) as
the intensive girls-only program (coverage 73%), but at a
greater cost and thus was dominated. The vaccination of
boys at the current coverage level for girls would achieve
additional health benefits at a cost of NZ$117,500 (95%
UI: $57,100 to $215,000; US$61,400) per QALYDW gained
compared to the current girls-only program (1G + B
compared to 1G). Adding boys to an intensified girls-only
program was not cost-effective (2G + B compared to 2G;
NZ$247,000 per QALYDW gained, 95% UI: $119,000 to
$474,000; US$128,000).
Females gained more QALYsDW from vaccination than
boys, even when the marginal change was from girls-
only to boys’ and girls’ vaccination (Table 3). For ex-
ample, the 2G + B interventions (i.e., both girls and boys
at 73% vaccine coverage) compared to 2G still produced
more QALYsDW gained for each individual female than
male (0.0015 vs 0.006).
Figure 2 shows the cost-effectiveness acceptability
curves for the three of the four programs (1G + B does
not appear as it was dominated as shown in Figure 3)
and no HPV vaccination program. Up to a willingness-
to-pay of about NZ$17,000, no HPV vaccination is the
optimal decision, then girls-only as currently imple-
mented in New Zealand up to NZ$33,000, and from a
willingness-to-pay of NZ$33,000 to NZ$230,000 an in-
tensified girls-only program is optimal. Only above a
willingness-to-pay of NZ$230,000 would vaccination of
boys be optimal.
Scenario analyses indicate that regardless of either very
low vaccine costs or low administrative costs, adding the
vaccination of boys was not found to be cost-effective
(Table 4). Increasing coverage in girls (2G) was consist-
ently more cost-effective than including boys. Applying
a 0% discount rate to costs and QALYsDW still did not
lead to the boys programs being cost-effective compared
with girls-only programs. However, by combining both
very low cost vaccine (NZ$1) with low administration
costs, all incremental comparisons including boys
compared to girls’ vaccination became dominant. In a
threshold analysis, we found that vaccination of boys
in addition to girls only became cost-effective (at a
willingness-to-pay threshold of $45,000 per QALYDW
gained) when the combined administration and vaccine
costs were $125 per dose or less (Figure 4), corresponding
to an estimated maximum cost per vaccinated individual
of $375.
We undertook sensitivity analyses to explore which in-
put parameter uncertainty was driving most of the un-
certainty in outputs (i.e., net cost, QALYsDW gained and
the ICER) (see Additional file 1: Figure S1). In Table 4,
we explored possible underestimation of comparative
advantage for MSM in the boys’ and girls’ vaccination
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Table 2 Total population level costs, QALYsDW gained and ICERs (95% uncertainty intervals) arising from vaccinating 12-year-olds (boys and girls) in New
Zealand in 2011, for the two interventions each compared to no vaccination program and for incremental comparisons











to the girls NZ
program in 2011
Intervention 2G + B:






1G + B c.f.
Intervention 1G
[C] Intervention
2G + B c.f.
Intervention 1G + B
[D] Intervention 2G +




$10,332 $14,955 $21,157 $30,632 $4,624 $10,826 $8,252 $15,676
($8,537 - $12,383) ($11,877 - $18,491) ($17,482 - $25,360) ($24,325 - $37,873) ($829 - $8,656) ($8,945 - $12,977) ($544 - $16,561) ($12,449 - $19,382)
Net cost (NZ
$; 1,000 s)
$4,644 $7,326 $13,610 $21,474 $2,683 $8,966 $7,864 $14,147
($2,269 - $7,045) ($3,873 - $11,126) ($9,223 - $18,370) ($14,932 - $28,858) ($-784 - $6,409) ($6,643 - $11,406) ($296 - $15,921) ($10,588 - $17,975)
QALYsDW
gained
267 350 350 413 83 83 63 63
(162–413) (218–530) (222–529) (266–608) (48–127) (47–134) (19–115) (33–104)
ICER* $18,800 $22,300 $41,100 $54,600 $33,500 $118,000 $148,000 $247,000
($6,500 - $36,700) ($9,500 - $41,100) ($20,700 - $70,000) ($29,900 - $90,400) ($-10,700 - $88,600) ($57,100 - $215,000) ($1,300 - $438,000) ($119,000 - $474,000)



















Table 3 Incremental costs, QALYsDW gained and ICERs per individual 12-year-old over their whole lives (expected value analysis)
Baseline Each intervention compared to no HPV vaccination Incremental comparisons
Intervention 1G:
Replicating the girls-only




Intervention 1G + B:
Adding boys to the girls
NZ program in 2011
Intervention 2G + B: Adding






1G + B c.f.
Intervention1G
[D] Intervention





$43,807 $81 $129 $235 $372 $47 $154 $244
QALYsDW gained (all individuals regardless of vaccination status)
Total
population
26.2830 0.0045 0.0059 0.0059 0.0069 0.0014 0.0014 0.0010
Males 26.3533 0.0025 0.0032 0.0033 0.0038 0.0007 0.0009 0.0006




$18,100 $21,900 m $53,700 $34,000 $111,000 $234,000



















program (1G + B) compared to girls only (1G). To do
this, we took an extreme case and removed all of the
herd immunity cancer reduction benefits (i.e., anal and
oropharyngeal) for males in the 1G program and com-
pared this to the benefits of our ‘best’ 1G + B model (i.e.,
with anal and oropharyngeal male cancer benefits rein-
troduced. In this analysis the estimated ICER was
$80,000 per QALYDW gained, which is still far above a
willingness-to-pay threshold of $45,000. Additionally, a
Tornado Plot for the ICER for 1G + B compared to 1G
is shown in Additional file 1: Figure S1. Uncertainty
about the parameter for marginal HPV reduction from
vaccinating boys in addition to girls was the biggest
driver of uncertainty, but even using the 97.5th percentile
value of these marginal proportionate reductions in
HPV (i.e., assuming the greatest incremental benefit for
adding boys vaccination), the ICER was still greater than
$75,000 per QALYDW gained (holding all other parame-
ters at their expected value). In a cost threshold analysis
for the most favourable and extreme scenario for boys’
vaccination (excluding herd immunity benefits related to
anal and oropharyngeal cancers for males when only fe-
males vaccinated), we found that the combined cost of
the vaccine and administration would need to be $167
per dose or lower (i.e., 34% less than best model ex-
pected price of $254 and 34% higher than best model’s
cost-effectiveness threshold price of $125 ) for vaccin-
ation to be considered cost-effective at a willingness-to-
pay threshold of NZ$45,000/QALYDW (see Additional
file 1: Figure S2).
Discussion
Discussion of main findings and interpretation
Our finding that HPV vaccination of boys was not cost-
effective when vaccination coverage in a girls-only pro-
gram was high (>50%) was consistent with other modeling
on the incremental cost-effectiveness of adding boys to
girls-only vaccination programs [1,35]. Specifically, we
Figure 2 Multiple cost-effectiveness acceptability curves for three HPV vaccination programs and no HPV vaccination. *when 2G + B
becomes preferred.
Figure 3 Cost-effectiveness plane for the two girls-only HPV vaccination programs and adding boys to the intensified girls-only
program compared to no HPV vaccination (bold black lines join average values).
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Table 4 Scenario analyses (expected value analysis; average costs and QALYsDW gained per individual 12-year-old over their whole lives
Each intervention compared to no HPV vaccination Incremental comparisons









B: Adding BOYS to
the GIRLS NZ
program in 2011
Intervention 2G + B:















2G + B c.f.
Intervention
2G
From Table 3, expected value only analysis Net cost
(NZ$)
$81 $129 $235 $372 $47 $154 $244
QALYsDW
gained
0.0045 0.0059 0.0059 0.0069 0.0014 0.0014 0.0010
ICER $18,100 $21,900 $40,000 $53,700 $34,000 $111,000 $234,000
Vaccine price halved (NZ$56) Net cost
(NZ$)
$41 $68 $154 $248 $27 $112 $180
QALYsDW
gained
0.0045 0.0059 0.0059 0.0069 0.0014 0.0014 0.0010
ICER $9,200 $11,600 $26,200 $35,800 $19,000 $81,300 $173,000
Very low vaccine price ($7.46) = GAVI price ~ US$5) Net cost
(NZ$)
$7 $16 $84 $142 $9 $76 $126
QALYsDW
gained
0.0045 0.0059 0.0059 0.0069 0.0014 0.0014 0.0010
ICER $1,600 $2,800 $14,300 $20,500 $6,500 $55,300 $121,000
Highly hypothetical vaccine price $NZ 1 Net cost
(NZ$)
$3 $10 $75 $129 $7 $72 $119
QALYsDW
gained
0.0045 0.0059 0.0059 0.0069 0.0014 0.0014 0.0010
ICER $700 $1,700 $12,800 $18,600 $4,900 $52,200 $115,000




$-4 $14 $61 $138 $18 $65 $124
QALYsDW
gained
0.0045 0.0059 0.0059 0.0069 0.0014 0.0014 0.0010
ICER Dominant $2,400 $10,400 $20,000 $12,800 $47,000 $119,000




$-80 $-103 $-99 $-110 $-22 $-18 $-7
QALYsDW
gained
0.0046 0.0059 0.0058 0.0069 0.0013 0.0012 0.0010



















Table 4 Scenario analyses (expected value analysis; average costs and QALYsDW gained per individual 12-year-old over their whole lives (Continued)




$-77 $-99 $-90 $-94 $-22 $-12 $5
QALYsDW
gained
0.0045 0.0059 0.0059 0.0069 0.0014 0.0014 0.0010
ICER Dominant Dominant Dominant Dominant Dominant Dominant $5,000
Discount rate 0% Net cost
(NZ$)
$-28 $-23 $80 $183 $5 $108 $205
QALYsDW
gained
0.0135 0.0186 0.0190 0.0233 0.0051 0.0055 0.0047
ICER Dominant Dominant $4,200 $7,900 $1,000 $19,400 $43,900




$123 $186 $293 $443 $63 $170 $257
QALYsDW
gained
0.0025 0.0031 0.0030 0.0035 0.0006 0.0006 0.0004
ICER $50,100 $59,900 $96,500 $127,000 $97,000 $294,000 $695,000
Excluding unrelated health system costs † Net cost
(NZ$)
$73 $117 $222 $356 $44 $150 $240
QALYsDW
gained
0.0045 0.0059 0.0059 0.0069 0.0014 0.0014 0.0010
ICER $16,200 $19,800 $37,900 $51,500 $31,500 $109,000 $231,000
Excluding disease DWs (i.e., no morbidity impacts
of HPV-related disease) ^
Net cost
(NZ$)
$81 $129 $235 $372 $47 $154 $244
QALYsDW
gained
0.0011 0.0016 0.0017 0.0022 0.0006 0.0007 0.0006
ICER $76,500 $79,800 $137,000 $166,000 $86,200 $233,000 $383,000
Excluding both background morbidity and disease




$81 $129 $235 $372 $47 $154 $244
QALYsDW
gained
0.0015 0.0023 0.0024 0.0031 0.0008 0.0009 0.0009
ICER $53,100 $56,300 $96,700 $119,000 $62,700 $171,000 $284,000
Excluding herd immunity benefits related to anal
and oropharyngeal cancers for males when only
females vaccinated: 1G (i.e., considering








† That is ignoring the health costs from diseases other than those specifically modeled, which increase net costs as living longer is associated with costs from (other) future disease and disability.
^ That is the DWs for cancers, CIN and anogenital warts states are all set to zero – but the background morbidity is retained. The health gain realized from HPV vaccination is therefore only from preventing premature



















found that providing vaccination of boys at the current
coverage level for girls would cost US$61,400 per QALY
gained (NZ$118,000, 95% UI: $57,100 to $215,000) com-
pared to the current girls-only program. For comparison
to other international studies, it is useful to use US dollars.
In the base case, we assumed the current New Zealand
vaccine cost of US$59 (NZ$113) per dose and administra-
tive costs of US$73 (NZ$141) per dose. By comparison,
US models (which do not generally assume vaccine is de-
livered as a publicly-funded health service) assumed vac-
cine costs (in 2011 USD) of US$101-135 per dose [35,36]
and US$61 administration costs per dose [35]. Those same
studies, when comparing the addition of boys to girls-only
vaccination programs, and including all HPV-related dis-
eases and similar vaccine efficacy and duration to our study,
were found to be more cost-effective than our study, ran-
ging from US$26,000 [36] to $41,000 [35] per QALY for
coverages under 50% and $62,000/QALY for coverages up
to 70% [37]. While direct comparisons between cost-
effectiveness analyses are difficult, the observed differences
in cost-effectiveness are most likely due to varying disutility
assigned to genital warts and CIN states (less in our model
than in the US studies, see Additional file 1: Table S1; and
uncertainty analyses in our parallel girls-only vaccination
paper demonstrated that disutility assigned to these states
was a major driver of uncertainty in the final ICER [20]).
Also, the inclusion of future health system costs in our
model will slightly lessen cost-effectiveness (scenario ana-
lyses about excluding unrelated health system costs show
little impact, see Table 4) and our use of a cohort (rather
than a population-wide) model may have influence. Our
study also found that vaccination of boys only became cost-
effective under the conditions of both an extremely low
vaccine price (NZ$1 per dose) and with very low adminis-
tration costs (NZ$19 per dose), up to a maximum total cost
of NZ$125 per dose delivered. However, even at a lower
cost per dose delivered, because a more intensive female-
only program is equally effective and less costly than adding
boys to the current program, increasing coverage in girls
would generally remain a preferable strategy if this could be
achieved.
Study strengths and limitations
A strength of this study is its potential to fill a gap in
the knowledge base for New Zealand policy makers who
may be considering what next after the relatively suc-
cessful implementation of a girls-only HPV program.
More broadly it adds to the relatively small number of
studies that have addressed the cost-effectiveness of vac-
cinating boys in a publicly funded system.
Nevertheless, a limitation is the lack of local data to
build a dynamic HPV infection model and thus, our reli-
ance on HPV reduction results from a Canadian dy-
namic model. Thus we implicitly assumed that sexual
behavior in New Zealand and Canada are broadly similar
for reasons outlined in the Methods section. This should
not be overly problematic if vaccine coverage rates are
not correlated with level of sexual behavior or factors
which influence choice of sexual partner [38]. Further-
more, refined and improved HPV modeling specific to
New Zealand would probably not alter our conclusion
that vaccination of boys is not cost-effective using a NZ
Figure 4 Cost threshold analysis for the combined vaccine + administration costs per dose for the best model adding boys to the
girls-only program. Incremental cost-effectiveness ratio of adding boys to the current girls-only program (1G + B), compared to the current
girls-only program (1G), as a function of cost per dose delivered (including vaccine and administration costs).
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$45,000 per QALY threshold (see Additional file 1: Figure
S1). Rather, a reduction in vaccine cost – perhaps plaus-
ible in the future – is more likely to influence whether
vaccination of boys is cost-effective in New Zealand (see
Table 4 and Additional file 1: Figure S1). That is, uncer-
tainty in applying Brisson et al. outputs (based on their
model assumptions, Canadian sexual contact patterns,
etc.) to the New Zealand situation – whilst important –
does not appear to be enough to alter the general con-
clusion that vaccinating boys in New Zealand is not
cost-effective (in the absence of large vaccination price
reductions). Another related issue was our use of a
‘steady state’ of HPV reduction in our population model.
Our model estimates likely health impacts, costs and
cost-effectiveness for cohorts of 12-year-olds one to
three decades into the future after the first cohort is
vaccinated. This is a robust baseline model for the fol-
lowing reasons. First even for the first cohort vacci-
nated, they will still receive the benefits of direct
immunity (i.e., the majority of the benefit from HPV
16/18 reduction, as herd effects are smaller for these
HPV types, and also much of benefit from HPV 6/11
reduction, which has greater herd immunity [13]). The
first cohort vaccinated will also receive the benefit of
herd immunity from vaccination of the cohort’s immedi-
ate age contemporaries and subsequent vaccination of
younger cohorts and additionally some herd immunity
from older cohorts included in the catch-up program.
Girls up to nine years older than the modeled cohort (i.e.,
born in 1990 or later) were offered vaccination, with
achieved three-dose coverage in the range 37-54% [39].
Last, there is a ‘lead time’ benefit. For example, those vac-
cinated at age 12 years likely have a modal age of coitarche
of 15–18 years [30], and a period of maximum exposure
to HPV, due to multiple sexual partners, from age 15 to
30 years. This cohort will start to benefit from herd
immunity as previous modeling studies e.g., [15] and now
observed data from several countries [40] suggest that
HPV prevalence is likely to drop rapidly after the intro-
duction of HPV vaccination.
We did not include any costs associated with starting-up
a boys’ vaccination program, as these would likely be com-
paratively small when considered over the longer term and
because including boys is extending the existing girls-only
program, rather than a new program. (Scenario analyses
available from the authors on request confirm this). We
also did not model different coverage rates for boys and
girls, given we expected minimal differences can be
achieved, particularly with school-based vaccination pro-
grams. We did not include the health benefits of cross-
protection of the quadrivalent vaccine against other HPV
strains which cause disease; such analyses would likely have
only a minor positive impact on QALYs gained and there-
fore only modestly affect cost-effectiveness [41]. Our
modeling does not separately model MSM, although we
did conduct a scenario analysis which removed the herd
immunity cancer reduction benefits for males in the girls-
only vaccination program (1G). We compared these results
with the benefits of adding boys to the vaccination program
(1G + B) and included MSM-attributable warts and cancers
in the disease incidence data that populates the model.
Should a targeted program be able to successfully deliver
vaccination to MSM at a young age (e.g., in primary care
settings), it seems highly likely that this would be cost-
effective [17].
Our costing data for vaccination delivery were based on
official Ministry of Health data which include funding to
cover program management (a component which does not
seem to typically be included in the ‘administration costs’ of
other studies). We recognize that this cost and relatively
high vaccine costs do not account for future plausible de-
velopments (e.g., in changes in delivery (see below) or de-
clines in vaccine prices). The latter is particularly relevant
to New Zealand, which has a single government-owned
agency (Pharmac) that purchases pharmaceuticals for the
whole country and has recently taken over national-level
vaccine purchases (from the Ministry of Health). This de-
velopment could result in substantial reductions in vaccine
prices in future purchase arrangements.
Research implications
The cost-effectiveness results were sensitive to vaccine and
administration costs, suggesting an analysis of a vaccination
program with only two required doses would be useful in
future research. However, if the efficacy of two doses were
similar to that of three doses, vaccination of boys would still
not be cost-effective based on our findings from our ‘best’
model (i.e., that with current prices), unless the total cost
per vaccinated individual was less than NZ$375 (based on
our threshold analysis). For example, for incremental com-
parison B in Table 2 (1G + B c.f.1G) the cost of the inter-
vention (first row) would decrease by a third or $3610, and
the net incremental cost would therefore reduce by 40%
from $8,996 to $5390. Hence the ICER would also reduce
by 40% to about $70,400 per QALY gained.
If new evidence of lower vaccine bulk prices tendered by
developed countries becomes available, future modeling
may be worthwhile as it is likely to suggest improvements
in cost-effectiveness (lower ICERs). Nevertheless, from our
analyses, the vaccine price would have to be substantially
less than the NZ$113 per dose assumed here to include
boys in any vaccination program, and the overall costs of
delivering a dose would have to be less than NZ$125, or
less than an overall cost per vaccinated individual of NZ
$375. Countries with other school-based vaccination pro-
grams (e.g., the DTP booster given to 11-year-olds as per
the New Zealand schedule) could also explore the adminis-
trative cost savings by providing dual vaccination at this
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one service. Such combinations of ‘piggy-backing’ of ad-
ministration cost reductions along with reductions in vac-
cine price appear, in our modeling, to be the major way
that vaccination of boys could start to become cost-
effective in the current New Zealand setting.
Possible policy implications
Given the findings of this modeling, policy makers in set-
tings like New Zealand (with relatively low HPV coverage
for girls) should probably focus more on improving HPV
vaccination for girls than adding HPV vaccination for boys.
Indeed, they should probably set decision review dates
around HPV vaccination for boys out into the medium
term or at least until vaccine prices drop substantially.
If policy makers are under public pressure to provide vac-
cination for boys then they should ideally focus on ways to
reduce the overall cost per vaccinated individual, as this will
increase the cost-effectiveness of adding boys to the pro-
gram, for example via research around cost-reduction mea-
sures (e.g., how to reduce delivery costs and also how to
obtain lower cost vaccine as detailed in the section above).
They could also reassure the public that the initial most lo-
gical goal of achieving higher HPV vaccination coverage for
girls will actually produce substantial spillover benefits via
herd immunity for boys.
Conclusions
These modeling results suggest that in countries like New
Zealand, the health sector would get the best value-for-
money by further improving HPV vaccination coverage for
girls, rather than adding in the vaccination of boys. Never-
theless, if very low vaccine and program administration
costs are achieved in the future, vaccination of school boys
may become cost-effective.
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Additional file 1: Table S1. Input parameters to the modeling: selected
base case parameters. Table S2. Health system costs for different states
of disease in the Markov model. Figure S1. Tornado plot showing the
impact on the ICER comparing boys and girls vaccination with just girls
at about 50% vaccine coverage (1G + B compared to 1G) from using the
2.5th and 97.5th percentile value of each input parameter (from its
uncertainty distribution) whilst holding all other input parameters at their
expected value, for one population stratum (Māori population, most
deprived tertile). Figure S2. Cost threshold analysis for combined
vaccine + administration costs per dose, for the most favourable and
extreme scenario for boys’ vaccination (excluding herd immunity benefits
related to anal and oropharyngeal cancers for males when only females
vaccinated). Incremental cost-effectiveness ratio of adding boys to the
current girls-only program (1G + B), compared to the current girls-only
program (1G), as a function of cost per dose delivered (including vaccine
and administration costs).
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